Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-Restricted epitopes

International Journal of Cancer

Volumn 108, Issue 6, 2004, Pages 863-870

  Faure, Olivier ^a,b,f   Graff Dubois, Stéphanie ^a   Bretaudeau, Laurent ^b,c   Derré, Laurent ^c   Gross, David Alexandre ^a   Alves, Pedro M S ^a,e   Cornet, Sébastien ^a   Duffour, Marie Thérèse ^b   Chouaib, Salem ^a   Miconnet, Isabelle ^a   Grégoire, Marc ^c   Jotereau, Francine ^c   Lemonnier, François A ^d   Abastado, Jean Pierre ^b   Kosmatopoulos, Kostas ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b IDM (Immuno Designed Molecules)   (France)

^c INSTITUT DE BIOLOGIE   (France)

^d INSTITUT PASTEUR   (France)

^e CICP Centre of Research in Political Science   (Portugal)

^f IDM   (United States)

Author keywords

Cytotoxic T lymphocytes; Heat shock protein (Hsp) 70; HLA A*0201 restricted epitope; Immunotherapy; Tumor antigen

Indexed keywords

EPITOPE; HEAT SHOCK PROTEIN 70; HLA A ANTIGEN; TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING;

ANIMALS; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES; HLA ANTIGENS; HLA-A ANTIGENS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; MICE; MICE, TRANSGENIC; PEPTIDES; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9144273779     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11653     Document Type: Article

References (50)

1. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001;94:459-73.
2. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9.
3. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000;60:4845-9.
4. Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broadspectrum tumor immunotherapy. J Immunol 2002;169:575-80.
5. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res 1999;248:30-43.
6. Volm M, Mattern J, Stammler G. Up-regulation of heat shock protein 70 in adenocarcinomas of the lung in smokers. Anticancer Res 1995;15:2607-9.
7. Volm M, Koomagi R, Mattern J, Stammler G. Heat shock (hsp70) and resistance proteins in non-small cell lung carcinomas. Cancer Lett 1995;95:195-200.
8. Lazaris AC, Theodoropoulos GE, Davaris PS, Panoussopoulos D, Nakopoulou L, Kittas C, Golematis BC. Heat shock protein 70 and HLA-DR molecules tissue expression. Prognostic implications in colorectal cancer. Dis Colon Rectum 1995;38:739-45.
9. Lazaris AC, Chatzigianni EB, Panoussopoulos D, Tzimas GN, Davaris PS, Golematis BC. Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified. Breast Cancer Res Treat 1997;43:43-51.
10. Kontogeorgos G, Stefaneanu L, Kovacs K. Stress-response proteins in human pituitary adenomas. Expression of heat-shock protein 72 (HSP-72). Endocrine 1997:6:25-9.
11. Park CS, Joo IS, Song SY, Kim DS, Bae DS, Lee JH. An immunohistochemical analysis of heat shock protein 70, p53, and estrogen receptor status in carcinoma of the uterine cervix. Gynecol Oncol 1999;74:53-60.
12. Nanbu K, Konishi I, Komatsu T, Mandai M, Yamamoto S, Kuroda H, Koshiyama M, Mori T. Expression of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Correlation with clinicopathology, sex steroid receptor status, and p53 protein expression. Cancer 1996;77:330-8.
13. Nanbu K, Konishi I, Mandai M, Kuroda H, Hamid AA, Komatsu T, Mori T. Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Cancer Detect Prev 1998;22:549-55.
14. Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirnhofer S. Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy. Hum Pathol 1998;29:1050-5.
15. Nylandsted J, Brand K, Jaattela M. Heat shock protein 70 is required for the survival of cancer cells. Ann N Y Acad Sci 2000;926:122-5.
16. Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F, Jaattela M. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci USA 2000:97:7871-6.
17. Ravagnan L, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, Mak T, Jaattela M, Penninger JM, Garrido C, Kroemer G. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 2001;3:839-43.
18. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 1998;8:657-65.
19. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1993;178:1391-6.
20. Blachere NE, Udono H, Janetzki S, Li Z, Heike M, Srivastava PK. Heat shock protein vaccines against cancer. J Immunother 1993;14:352-6.
21. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, Udono H, Srivastava PK. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997;186:1315-22.
22. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8+ T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997;185:2043-51.
23. Michels AA, Kanon B, Konings AW, Ohtsuka K, Bensaude O, Kampinga HH. Hsp70 and Hsp40 chaperone activities in the cytoplasm and the nucleus of mammalian cells. J Biol Chem 1997;272:33283-9.
24. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA, Kosmatopoulos K. A general strategy to enhance immunogenicity of low-affinity HLA-A2, 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 2000;30:3411-21.
25. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986;95:99-105.
26. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
27. Katoh M, Koninkx J, Schumacher U. Heat shock protein expression in human tumours grown in severe combined immunodeficient mice. Cancer Lett 2000;161:113-20.
28. Johnsson A, Zeelenberg I, Min Y, Hilinski J, Berry C, Howell SB, Los G. Identification of genes differentially expressed in association with acquired cisplatin resistance. Br J Cancer 2000;83:1047-54.
29. Patel B, Khaliq A, Jarvis-Evans J, Boulton M, Arrol S, Mackness M, McLeod D. Hypoxia induces HSP 70 gene expression in human hepatoma (HEP G2) cells. Biochem Mol Biol Int 1995;36:907-12.
30. Kaur J, Ralhan R. Induction of apoptosis by abrogation of HSP70 expression in human oral cancer cells. Int J Cancer 2000;85:1-5.
31. Gaudin C, Kremer F, Angevin E, Scott V, Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 1999;162:1730-8.
32. Zeh HJ, 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-94.
33. Oehler R, Pusch E, Zellner M, Dungel P, Hergovics N, Homoncik M, Eliasen MM, Brabec M, Roth E. Cell type-specific variations in the induction of hsp70 in human leukocytes by feverlike whole body hyperthermia. Cell Stress Chaperones 2001;6:306-15.
34. Polla BS. A role for heat shock proteins in inflammation? Immunol Today 1988;9:134-7.
35. Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, Appella E, DeLeo AB, Whiteside TL. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res 2002;62:3521-9.
36. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-17.
37. Nagorsen D, Keilholz U, Rivolfini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, Scheibenbogen C. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 2000:60:4850-4.
38. Grossmann ME, Davila E, Celis E. Avoiding tolerance aoainst prostatic antigens with subdominant peptide epitopes. J Immunother 2001;24:237-41.
39. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-86.
40. Trieb K, Lang S, Kotz R. Heat-shock protein 72 in human osteosarcoma: T-lymphocyte reactivity and cytotoxicity. Pediatr Hematol Oncol 2000;17:355-64.
41. Brink R, Goodnow CC, Crosbie J, Adams E, Eris J, Mason DY, Hartley SB, Basten A. Immunoglobulin M and D antigen receptors are both capable of mediating B lymphocyte activation, deletion, or anergy after interaction with specific antigen. J Exp Med 1992;176:991-1005.
42. Cibotti R, Kanellopoulos JM, Cabaniols JP, Halle-Panenko O, Kosmatopoulos K, Sercarz E. Kourilsky P. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci USA 1992;89:416-20.
43. Oukka M, Colucci-Guyon E, Tran PL, Cohen-Tannoudji M, Babinet C, Lotteau V, Kosmatopoulos K. CD4 T cell tolerance to nuclear proteins induced by medullary thymic epithelium. Immunity 1996;4:545-53.
44. Oukka M, Cohen-Tannoudji M, Tanaka Y, Babinet C, Kosmatopoulos K. Medullary thymic epithelial cells induce tolerance to intracellular proteins. J Immunol 1996;156:968-75.
45. Lo D, Freedman J, Hesse S, Palmiter RD, Brinster RL, Sherman LA. Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells. Eur J Immunol 1992;22:1013-22.
46. Cordaro TA, de Visser KE, Tirion FH, Schumacher TN, Kruisbeek AM. Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J Immunol 2002;168:651-60.
47. Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 1996;156:3151-8.
48. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+T lymphocytes. Proc Natl Acad Sci USA 1999;96:2982-7.
49. Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med 2000;191:1221-32.
50. Irvine KR, Parkhurst MR, Shulman EP, Tupesis JP, Custer M, Touloukian CE, Robbins PF, Yafal AG, Greenhalgh P, Sutmuller RP, Offringa R, Rosenberg SA, et al. Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. Cancer Res 1999;59:2536-40.